Zusammenfassung
Bei 18 Patienten mit essentieller Hypertonie wurde der Einfluß einer chronischen Alpha-und Betarezeptoren-Blockade mit Labetalol auf Plasmakatecholamine und Nierenfunktion untersucht. Plasmanoradrenalin und Adrenalin veränderten sich nach 6wöchiger Behandlung nicht signifikant, während die glomeruläre Filtrationsrate und der renale Plasmafluß um ungefähr 20% abnahmen (P<0,025). Die tubuläre Rejektionsfraktion von Natrium nahm um 36% zu (P<0.001), bei unveränderter Natrium-Ausscheidung im 24 h-Urin. Der geringgradige Abfall der glomerulären Filtrationsrate und des renalen Plasmaflusses scheint nur von geringer klinischer Bedeutung zu sein. Der fehlende Anstieg der Plasmakatecholamine unter der chronischen Alpha-und Betarezeptoren-Blockade mit Labetalol ist vereinbar mit einer selektiven postsynaptischen alpha-blockierenden Wirkung, während die präsynaptische Feedbackkontrolle der Katecholaminausschüttung unbeeinflußt bleibt. Zudem scheint die blutdrucksenkende Wirkung von Labetalol von Änderungen der Aktivität des sympathischen Nervensystems weitgehend unabhängig zu sen.
Summary
Plasma catecholamines and renal function were evaluated in 18 patients with essential hypertension treated with the alpha and beta adrenoceptor blocking agent, labetalol. Following 6 weeks of labetalol therapy, blood levels of epinephrine and norepinephrine remained unaltered. Glomerular filtration rate and renal plasma flow were decreased similarly by about 20% (P<0.025). Tubular rejection fraction of sodium was increased by 36% (P<0.001) while sodium excretion was comparable to control conditions. Labetalol's potential to cause a mild reduction in kidney function should be considered, but may have no clinical consequences in most hypertensive patients receiving such treatment. The lack of increased plasma catecholamine levels during therapy supports the concept that labetalol's alpha-blocking potential is limited to post-junctional receptors, leaving the prejunctional feedback control of catecholamine release intact. Moreover, labetalol's blood pressure-lowering mechanism may be largely independent of changes in sympathetic nervous activity.
References
Bello-Reuss, E., Trevino, D.L., Gottschalk, C.W.: Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption. J. Clin. Invest.57, 1104–1107 (1976)
Blakeley, A.G.H., Summers, R.J.: The effect of labetalol (AH 5158) on adrenergic transmission in the cat spleen. Br. J. Pharmacol.59, 643–650 (1977)
Bolli, P., Waal-Manning, H.J., Wood, A.J., et al: Experience with labetalol in hypertension. Br. J. Clin. Pharmacol.3, [Suppl. 3] 765–771 (1976)
Brogden, R.N., Heel, R.C., Speight, T.M., Avery, G.S.: Labetalol: A review of its pharmacology and therapeutic use in hypertension. Drugs15, 251–270 (1978)
Chapman, B.P., Veitch, A.G., Shepherd, B.: Labetalol and urinary catecholamines. Br. Med. J.2, 364 (1978)
Christensen, N.J., Trap-Jensen, J., Svendsen, T.L., Rasmusson, S., Nielsen, P.E.: Effect of labetalol on plasma noradrenaline and adrenaline in hypertensive man. Eur. J. Clin. Pharmacol14, 227–230 (1978)
Cubeddu, X.L., Barnes, E.M., Langer, S.Z., et al: Release of norepinephrine and dopamine β-hydroxylase by nerve stimulation I. role of neuronal and extraneuronal uptake and of presynaptic alpha receptors. J. Pharmacol. Exp. Ther.190, 431–450 (1974)
Da Prada, M., Zürcher, G.: Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline, and dopamine within the femtomole range. Life Sci.19, 1161–1174 (1976)
Dargie, H.J., Dollery, C.T., Daniel, J.: Labetalol in resistant hypertension. Br. J. Clin. Pharmacol.3 [Suppl. 3], 751–755 (1976)
Doggrell, S.A., Paton, D.M.: Effect of labetalol on the accumulation and release of noradrenaline in rat ventricle. Eur. J. Pharmacol.51, 303–307 (1978)
Edwards, R.C., Raftery, E.B.: Haemodynamic effects of longterm oral labetalol. Br. J. Clin. Pharmacol.3 [Suppl. 3], 733–736 (1976)
Frick, M.H., Pörsti, P.: Combined α and β adrenoceptor blockade with labetalol in hypertension. Br. Med. J.1, 1046–1048 (1976)
Glaubiger, G., Lefkowitz, R.J.: Elevated beta-adrenergic receptor number after chronic propranolol treatment. Biochem. Biphys. Res. Commun.78, 720–725 (1977)
Halter, J.P., Porte, D. Jr.: Plasma catecholamines in the evaluation of sympathetic nervous system function in man. Clin. Res.25, 295 A (1977)
Hamilton, C.A., Jones, D.H., Dargie, H.J., Reid, J.L.: Does labetalol increase excretion of urinary catecholamines? Br. Med. J.2, 800 (1978)
Hansson, B.G., Hökfelt, B.: Long-term treatment of moderate hypertension with penbutolol (Hoe 893 d) I. effects on blood pressure, pulse rate, catecholamines in blood and urine, plasma renin activity, and urinary aldosterone under basal conditions and following exercise. Eur. Clin. Pharmacol.9, 9–19 (1975)
Harris, D., Richards, D.A.: Labetalol and urinary catecholamines. Br. Med. J.2, 1673 (1977)
Kirpekar, S.M., Cervoni, P.: Effect of cocaine, phenoxybenzamine and phentolamine on the catecholamine output from spleen and adrenal medulla. J. Pharmacol. Exp. Ther.142, 59–70 (1963)
Kirpekar, S.M., Puig, M.: Effect of flow stop on noradrenaline release from normal spleens and spleens pretreated with cocaine, phentolamine or phenoxybenzamine. Br. J. Pharmacol.43, 359–369 (1971)
Kobayashi, K., Miura, Y., Tomioka, H., Sakuma, H., Adachi, M., Abe, K.: Interference with fluorometric assay of catecholamine by labetalol. Tohuku J. Exp. Med.126, 201–202 (1978)
Kolloch, R., Miano, L., De Quattro, V.: Labetalol and urinary catecholamines. Br. Med. J.1, 268–269 (1979)
Langer, S.Z.: Presynaptic regulation of catecholamine release. Biochem. Pharmacol.23, 1793–1800 (1974)
Louis, W.J., Christophidis, N., Brignell, M., Vijayasekaran, V., McNeil, J., Vajda, F.J.E.: Labetalol: Bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension. Aust. NZ J. Med.8, 602–609 (1978)
Mehta, J., Cohn, J.N.: Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects. Circulation55, 370–375 (1977)
Prichard, B.N.C., Boakes, A.J.: Labetalol in long-term treatment of hypertension. Br. J. Clin. Pharmacol.3, [Suppl. 3], 743–750 (1976)
Reubi, F.C.: Le retentissment rénal des traitements antihypertenseurs. J. Urol. Nephrol. (Paris)83, 296–302 (1977)
Reubi, F.C.: Role of physical factors in the acute changes in renal function elicited by antihypertensive drugs. Eur. J. Clin. Pharmacol.13, 185–193 (1978)
Schümann, H.J., Werner, U.: Hemmung der Hormonfreisetzung aus dem Nebennierenmark durch BAY a 6781, eine antihypertensiv interessante Substanz. Naunyn Schmiedebergs Arch. Pharmacol.268, 71–82 (1971)
Starke, K., Görlitz, B.D., Montel, H., Schümann, H.J.: Local α-adrenoceptor mediated feed-back inhibition of catecholamine release from the adrenal medulla? Experientia30, 1170–1172 (1974)
Vorburger, C., Riedwyl, H., Reubi, F.C.: Vergleichende Studien zwischen den renalen Clearances von51Cr-EDTA, Inulin und Natriumthiosulfat beim Menschen. Klin. Wochenschr.47, 415–420 (1969)
Weidmann, P., Beretta-Piccoli, C., Ziegler, W., Hirsch, D., De Châtel, R., Reubi, F.C.: Beziehungen zwischen Blutdruck, Blutvolumen, Plasma-Renin und Urin-Katecholaminen während Betablockade bei essentieller Hypertonie. Klin. Wochenschr.54, 765–773 (1976)
Weidmann, P., De Châtel, R., Ziegler, W.H., Flammer, J., Reubi, R.C.: Alpha and beta adrenergic blockade with orally administered labetalol in hypertension. Am. J. Cardiol.41, 570–576 (1978)
Weidmann, P., Beretta-Piccoli, C., Ziegler, W., Keusch, G., Glück, Z., Reubi, F.C.: Age versus urinary sodium for judging renin, aldosterone and catecholamine levels: Studies in normal subjects and patients with essential hypertension. Kidney Int.14, 619–628 (1978)
Zambraski, E.J., Di Bona, G.F., Kaloyanides, G.J.: Effect of sympathetic blocking agents on the antinatriuresis of reflex renal nerve stimulation. J. Pharmacol. Exp. Ther.198, 464–472 (1976)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Keusch, G., Weidmann, P., Ziegler, W.H. et al. Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension. Klin Wochenschr 58, 25–29 (1980). https://doi.org/10.1007/BF01477140
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01477140